Search
recombinant parathyroid hormone (1-84) (Natpara)
Indications:
- hypoparathyroidism (FDA-approved Jan 2015)
- patients not responding to calcium supplementation & 1,25-dihydroxyvitamin D [2]
- osteoporosis
Dosage:
- injection one a day
Adverse effects: (common)
- hypercalciuria, hypercalcemia, nausea
- osteosarcoma has been observed in rat studies [2]
Mechanism of action:
- may reduce risk of vertebral fractures in women with osteoporosis
General
recombinant protein; chimer
parathyroid hormone; parathormone; parathyrin (PTH)
endocrine agent
References
- Greenspan SL, Bone HG, Ettinger MP, Hanley DA, Lindsay R,
Zanchetta JR, Blosch CM, Mathisen AL, Morris SA, Marriott TB;
Treatment of Osteoporosis with Parathyroid Hormone Study Group.
Effect of recombinant human parathyroid hormone (1-84) on
vertebral fracture and bone mineral density in postmenopausal
women with osteoporosis: a randomized trial.
Ann Intern Med. 2007 Mar 6;146(5):326-39.
PMID: 17339618
- Reuters, Sept 12, 2014
U.S. FDA panel recommends approval of NPS hormone replacement
drug.
http://news.yahoo.com/u-fda-panel-recommends-approval-nps-hormone-replacement-214259435--finance.html
- FDA News Release. January 23, 2015
FDA approves Natpara to control low blood calcium levels in
patients with hypoparathyroidism.
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm431358.htm
Components
melphalan (Alkeran, L-PAM, L-sarcolysin phenylalanine mustard, melphalan flufenamide, Pepaxto)
prednisone (Deltasone, Orasone, Liquid Pred, Meticortin, Rayos)
thalidomide (Thalamid, Corronarobetin)